DAXOR CORP 10-Q Summary: Period Ended June 30, 1998
Business Context and Reporting Period
This Form 10-Q covers the quarterly and six-month periods ended June 30, 1998, for DAXOR Corporation. The company operates clinical laboratories, including blood and semen banking facilities, and is developing the Blood Volume Analyzer. Operations are currently constrained by legal proceedings with the New York State Department of Health regarding licensing for its banking facilities.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1998 | Six Months Ended June 30, 1997 |
|---|---|---|
| Total Revenues | $1,559,331 | $1,572,045 |
| Operating Revenues | $185,142 | $295,015 |
| Dividend Income | $1,024,325 | $1,070,612 |
| Net Income (Loss) | $(180,611) | $329,517 |
| Net Income (Loss) Per Share | $(0.04) | $0.07 |
| Cash and Cash Equivalents | $112,628 | $69,270 |
| Marketable Securities (Fair Value) | $41,034,130 | $40,347,085 |
| Total Assets | $42,033,372 | $41,322,592 |
| Total Liabilities | $7,284,890 | $8,404,868 |
| Shareholders' Equity | $34,748,482 | $32,917,724 |
| Loans Payable | $1,206,326 | $2,494,639 |
Material Changes vs. Prior Period
- Operating Revenue Decline: Operating revenues dropped 37% to $185,142 from $295,015 due to legal actions preventing the acceptance of new clients in blood and semen banking.
- Net Loss: The company reported a net loss of $180,611 for the six months ended June 30, 1998, compared to a net income of $329,517 in the prior year period.
- Interest Expense Surge: Net interest expense increased significantly to $420,755 from $48,561 in the prior year.
- Investment Portfolio: The company holds a substantial portfolio of marketable securities valued at $41.0 million, representing a net unrealized gain of $17.5 million (74.5% over cost).
- Debt Reduction: Total loans payable decreased by approximately $1.3 million, primarily due to repayments of short-term margin debt.
Outlook, Risks, and Management Commentary
- Legal Contingencies: Ongoing negotiations with the New York State Department of Health may result in a settlement that could reopen blood and semen banking facilities. Until resolved, the company cannot accept new clients in these divisions.
- Product Development: The company has received Letters of Intent from ten major teaching hospitals to test the Blood Volume Analyzer. Management expects this product to eventually diminish the relative significance of banking services.
- Liquidity: The company maintains adequate liquid capital to sustain current operations and marketing efforts for the Blood Volume Analyzer. However, a nationwide expansion of blood banking would require additional capital.
- Strategic Acquisitions: DAXOR is in negotiations to acquire the assets of Wellport, Inc., the manufacturer of the patented Blood Volume Analyzer injection kit.
- Y2K Compliance: A contract has been initiated for a new computer system to be installed within 90 days to address Year 2000 issues.
Investor Verification Checklist
- Verify the status of negotiations with the New York State Department of Health regarding the reopening of blood and semen banking facilities.
- Confirm the timeline and commercial viability of the Blood Volume Analyzer, including the status of the ten Letters of Intent.
- Assess the sustainability of the investment portfolio strategy, noting that a significant portion of equity is derived from unrealized gains on securities.
- Monitor the outcome of potential asset acquisition of Wellport, Inc.
- Review the impact of high interest expenses on future profitability as the company transitions away from banking services.